FILE 'HOME' ENTERED AT 15:30:51 ON 16 JUL 2003

=> fil medline caplus cancerlit
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 15:31:07 ON 16 JUL 2003

FILE 'CAPLUS' ENTERED AT 15:31:07 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 15:31:07 ON 16 JUL 2003

=> s hexadecylphosphocholine
L1 618 HEXADECYLPHOSPHOCHOLINE

=> s l1 and gene therapy
L2 1 L1 AND GENE THERAPY

=> d

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2001:923645 CAPLUS
DN 136:48434
TI Combination product intended for carrying out a cytotoxic treatment, in
particular an antitumour treatment, in a mammal
IN Meyer, Olivier
PA Transgene S.A., Fr.
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2001095946 A2 20011220 WO 2001-IB1287 20010613
WO 2001095946 A3 20020906
W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR
EP 1289568 A2 20030312 EP 2001-947745 20010613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR
US 2002025941 A1 20020228 US 2001-880038 20010614
PRAI FR 2000-7604 A 20000614
US 2000-246090P P 20001107
WO 2001-IB1287 W 20010613
OS MARPAT 136:48434

=>
Connection closed by remote host

Welcome to STN International! Enter x:x

LOGINID:ssspta1633jxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

********** Welcome to STN International **********

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

********** STN Columbus **********

FILE 'HOME' ENTERED AT 15:52:21 ON 16 JUL 2003

=> fil medline caplus embase cacnerlit biosis
'CACNERLIT' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):cancerlit
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 15:52:42 ON 16 JUL 2003

FILE 'CAPLUS' ENTERED AT 15:52:42 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:52:42 ON 16 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 15:52:42 ON 16 JUL 2003

FILE 'BIOSIS' ENTERED AT 15:52:42 ON 16 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s hexadecylphosphocholine
L1 1105 HEXADECYLPHOSPHOCHOLINE

=> s l1 and cytotox?
L2 219 L1 AND CYTOTOX?

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 80 DUP REM L2 (139 DUPLICATES REMOVED)

=> s l3 and (treat? or therap?)
4 FILES SEARCHED...
L4 46 L3 AND (TREAT? OR THERAP?)

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 46 DUP REM L4 (0 DUPLICATES REMOVED)

=> d 15-22 ti so

L5 ANSWER 15 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
SO Biochimica et Biophysica Acta, (Nov. 11, 1998) Vol. 1414, No. 1-2, pp. 238-248.
ISSN: 0006-3002.

L5 ANSWER 16 OF 46 CAPLUS COPYRIGHT 2003 ACS
TI The effect of hexadecylphosphocholine on the proliferation of human keratinocytes in vitro and in vivo
SO Drugs of Today (1998), 34(Suppl. F), 97-105
CODEN: MDACAP; ISSN: 0025-7656

L5 ANSWER 17 OF 46 CAPLUS COPYRIGHT 2003 ACS
TI Morphological changes and cytokine gene expression in tumor xenografts following treatment with the alkylphosphocholines hexadecylphosphocholine and perifosine
SO Drugs of Today (1998), 34(Suppl. F), 15-26
CODEN: MDACAP; ISSN: 0025-7656

L5 ANSWER 18 OF 46 MEDLINE
TI The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine.
SO BIOCHIMICA ET BIOPHYSICA ACTA, (1998 Jan 5) 1389 (1) 1-12.
Journal code: 0217513. ISSN: 0006-3002.

L5 ANSWER 19 OF 46 CAPLUS COPYRIGHT 2003 ACS
TI The influence of 1-.beta.-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells
SO Leukemia (1997), 11(12), 2079-2086
CODEN: LEUKED; ISSN: 0887-6924

L5 ANSWER 20 OF 46 CAPLUS COPYRIGHT 2003 ACS
TI Synergistic cytotoxic effects of ether phospholipid analogs and ionizing radiation in human carcinoma cells
SO Radiotherapy and Oncology (1997), 43(3), 293-301
CODEN: RAONDT; ISSN: 0167-8140

L5 ANSWER 21 OF 46 MEDLINE
TI Antiproliferation effects of hexadecylphosphocholine on solid tumour and leukaemia selectively in vitro.
SO DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, (1997) 23 (3-4) 97-102.
Journal code: 7802135. ISSN: 0378-6501.

L5 ANSWER 22 OF 46 CAPLUS COPYRIGHT 2003 ACS
TI Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts
SO Anticancer Research (1997), 17(1A), 37-43
CODEN: ANTRD4; ISSN: 0250-7005

=> s l5 and (interleukin? or IL?)
L6 8 L5 AND (INTERLEUKIN? OR IL?)

=> d 1-8 ti so

L6 ANSWER 1 OF 8 MEDLINE
TI Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism.
SO INTERNATIONAL JOURNAL OF CANCER, (2001 May 1) 92 (3) 426-33.
Journal code: 0042124. ISSN: 0020-7136.

L6 ANSWER 2 OF 8 MEDLINE
TI Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis.
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, (2001 Feb 1) 49 (2) 415-9. Ref: 57
Journal code: 7603616. ISSN: 0360-3016.

L6 ANSWER 3 OF 8 MEDLINE
TI Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi.
SO ACTA TROPICA, (2000 Mar 25) 75 (2) 219-28.
Journal code: 0370374. ISSN: 0001-706X.

L6 ANSWER 4 OF 8 MEDLINE
TI Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines.
SO EUROPEAN JOURNAL OF CANCER, (1994) 30A (14) 2143-50.
Journal code: 9005373. ISSN: 0959-8049.

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
TI Combination product intended for carrying out a cytotoxic
treatment, in particular an antitumour treatment, in a mammal
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
TI Morphological changes and cytokine gene expression in tumor xenografts
following treatment with the alkylphosphocholines hexadecylphosphocholine and perifosine
SO Drugs of Today (1998), 34(Suppl. F), 15-26
CODEN: MDACAP; ISSN: 0025-7656

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
TI Influence of hexadecylphosphocholine (miltefosine) on cytokine
synthesis and biological responses
SO Advances in Experimental Medicine and Biology (1996), 416(Platelet-
Activating Factor and Related Lipid Mediators 2), 181-187
CODEN: AEMBAP; ISSN: 0065-2598

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
TI Maleic anhydride copolymers as antidotes for the cytotoxicity of
neoplasm inhibitors
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW

=> d 5 ab

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
AB The present invention relates to a combination product comprising at least
one nucleic acid contg. a sequence encoding a polypeptide or interest and
at least one phospholipid of interest, for use which is simultaneous,
consecutive or spread out over time, characterized in that said
polypeptide and phospholipid of interest have cytotoxic activity.

=> d 5

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:923645 CAPLUS
DN 136:48434
TI Combination product intended for carrying out a cytotoxic
treatment, in particular an antitumour treatment, in a mammal
IN Meyer, Olivier
PA Transgene S.A., Fr.
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001095946	A2	20011220	WO 2001-IB1287	20010613
WO 2001095946	A3	20020906		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1289568	A2	20030312	EP 2001-947745	20010613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2002025941	A1	20020228	US 2001-880038	20010614
PRAI FR 2000-7604	A	20000614		
US 2000-246090P	P	20001107		
WO 2001-IB1287	W	20010613		

OS MARPAT 136:48434

=> FIL STNGUIDE
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 28.43 28.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -0.65 -0.65

FILE 'STNGUIDE' ENTERED AT 15:57:09 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 11, 2003 (20030711/UP).

=> d l6 ab
YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 1 OF 8 MEDLINE
AB This study was undertaken to investigate the antitumor effect of liposomal
hexadecylphosphocholine (L-HPC), a synthetic phospholipid
encapsulated into multilamellar vesicles (MLV). The effect of these
liposomes was tested in an orthotopic nude mouse model using the human
mammary carcinomas MDA-MB 435 and 231. The main interest of the
investigation was to study whether activated macrophages are substantially
involved in the tumor growth inhibition mechanism. The growth of both
MDA-MB 435 and 231 tumors in the mammary fat pad was significantly
inhibited by a 14-day intraperitoneal therapy with L-HPC. The
remaining tumors were shown to be heavily infiltrated with macrophages.
In vitro studies of mPEM demonstrated a significant induction of
macrophage-mediated tumor cytotoxicity (MMCTX) against the 2
cell lines by L-HPC. The L-HPC-mediated activation mechanism was
characterized to be IL-6 and TNFalpha dependent but rather
independent of IL-1alpha and nitric oxide (NO). NMA, a specific
inhibitor of NO production, did not inhibit L-HPC-induced MMCTX.
Furthermore, L-HPC was shown to upregulate the matrixmetalloproteinases
MMP-9 and MMP-2 secretion into the supernatant. Considering cytokine
release and production of collagenases, the L-HPC-induced macrophage
activation cascade is assumed to be comparable with that of classical
activators such as lipopolysaccharide (LPS) and interferon (IFN) gamma.
As far as NO production is considered, the L-HPC activation mechanism
differs from that caused by LPS and IFN gamma.
Copyright 2001 Wiley-Liss, Inc.

=> d l6 4-8 ab
YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 4 OF 8 MEDLINE
AB The molecular and cellular effects of the anti-neoplastic
alkylphospholipid hexadecylphosphocholine (Miltefosine, MIL) on
parameters associated with growth and differentiation of human myeloid
leukaemic cell lines U937, KG1 and KG1a were investigated. On a cellular
level, MIL has dose-dependent differentiation-inducing growth-promoting
and cytotoxic activities exemplified by induction of respiratory
burst activity, stimulation of interleukin-3 (IL-3)/granulocyte-macrophage colony stimulating factor (GM-CSF)-dependent
growth of the KG1 cell line in soft agar culture, inhibition of cellular
net growth and finally cell death. By northern blot analysis,
transcription of functional receptors for IL-3, GM-CSF, G-CSF
and FcRI were studied. It was shown that MIL has stimulatory activity on
IL-3 and GM-CSF receptor gene transcription. In addition, the
transcription of proliferation- and differentiation-associated proteins,
namely histone subtypes, c-myc and NF-kappa B p50, were studied. MIL
suppressed c-myc and enhanced NF-kappa B p50 transcription in the U937
cell line, comparable to the well-characterised differentiation-inducing
phorbolester 12-O-tetradecanoylphorbol-13-acetate (TPA). We conclude that
the interaction of MIL with its molecular target(s) in myeloid cells
induces molecular and cellular effects associated with induction of
differentiation, distinct from its cytotoxic activity.

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
AB The present invention relates to a combination product comprising at least
one nucleic acid contg. a sequence encoding a polypeptide or interest and
at least one phospholipid of interest, for use which is simultaneous,
consecutive or spread out over time, characterized in that said
polypeptide and phospholipid of interest have cytotoxic activity.

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
AB Hexadecylphosphocholine (HPC) is active against exptl. and clin.
breast cancer in vivo, however the mechanisms of its action are unclear.
The aims of this study were to further investigate the role of
immunomodulation in the antitumor activity of HPC and to study the novel
analog octadecyl (1,1-dimethyl-piperidino-4-yl)phosphate (D-21266,
perifosine). Earlier investigations have demonstrated that redn. in tumor
vol. in MT-1 human breast xenografts by HPC is accompanied by infiltration
of immune cells. In this paper the earlier studies have been extended to
investigate the functional activity of the infiltrating cells. MT-1
tumors transplanted s.c. to mammary fat pads of 12-wk-old NCR/nu mice were
allowed to grow for approx. 22 days. HPC in 10% Tween 80/saline, or
D-21266 in saline was administered orally (50 mg/kg/day) for 5 days. Ten
percent Tween 80/saline alone was administered to control mice at same
time. One week after the end of treatment, mice were killed and
secondary immune tissues and tumors removed for histol. and reverse
transcriptase-polymerase chain reaction (RT-PCR) anal. Cytokine mRNA
expression was assessed by RT-PCR. MRNA for interferon-.gamma.,
interleukin-1.beta. and tumor necrosis factor-.alpha. was detected
in HPC-treated tumors. These effects did not occur in control
tumors or with std. cytotoxic therapy, thus the
results provide further support for the suggestion that immunomodulation
may play a role in the antitumor effects of HPC. D-21266 showed similar
antitumor and morphol. effects against MT-1 xenografts indicating that
addnl. studies of this analog are warranted.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
AB In the presence of interleukin-3 or GM-CSF, miltefosine
stimulated rat and mouse bone marrow cells, whereas it had no effect in
the absence of interleukin-3 or GM-CSF. In addn., in rats,
miltefosine decreased the suppression of granulocytes after
cytotoxic treatment with cyclophosphamide, and when given for one week before the cytotoxic agent, miltefosine
protected the progenitor cells. In human myeloid cell lines, miltefosine
increased the interleukin-3 receptor .alpha. and .beta.c mRNA
levels, but had no effect on GM-CSF receptor mRNA levels. Miltefosine
also influenced the formation of TNF.alpha. in peripheral blood cells
stimulated with Con A or LPS and had variable effects when given alone.
Miltefosine did not affect the basal level of mRNA for TNF.alpha. or
GM-CSF when given alone, but caused a prolongation of the increase in both
mRNA species in response to Con A. Thus, miltefosine has a growth
stimulatory effect on bone marrow cells, possibly by increasing expression
of cytokine receptors. This activity may be useful in conjunction with
myelosuppressive chemotherapy.

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
AB Half-amide:half-imide copolymers comprising ethylene and maleic anhydride
moieties (structure given), specifically carbetimer (I; a/b = 1:2-5),
decrease the cytotoxic side effects of neoplasm inhibitors.
Mice treated i.v. with 21 mg adriamycin/kg died within 5 days.
When 1700 mg I/kg was administered concomitantly, no lethality was shown
for >30 days

=> fil medline biosis caplus cancerlit embase
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.42 37.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 - 3.25

FILE 'MEDLINE' ENTERED AT 16:09:27 ON 16 JUL 2003

FILE 'BIOSIS' ENTERED AT 16:09:27 ON 16 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CAPLUS' ENTERED AT 16:09:27 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 16:09:27 ON 16 JUL 2003

FILE 'EMBASE' ENTERED AT 16:09:27 ON 16 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s hexadecylphosphocholine or miltefosine
L7 1680 HEXADECYLPHOSPHOCHOLINE OR MILTEFOSINE

=> s l7 and (interleukin-2 or il-2)
L8 39 L7 AND (INTERLEUKIN-2 OR IL-2)

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9 21 DUP REM L8 (18 DUPLICATES REMOVED)

=> d 1-21 ti so

L9 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Incensole and furanogermacrens and compounds in treatment for inhibiting
neoplastic lesions and microorganisms
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

L9 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Methods and compositions for enhancing pharmaceutical treatments
SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.
CODEN: USXXCO

L9 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Therapeutic modulation of the tumor inflammatory response
SO U.S. Pat. Appl. Publ., 12 pp
CODEN: USXXCO

L9 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Combination product intended for carrying out a cytotoxic treatment, in
particular an antitumour treatment, in a mammal
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L9 ANSWER 5 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Cutaneous lymphomas.
SO Current Problems in Dermatology, (2000) 12/1 (25-29).
Refs: 25
ISSN: 1040-0486 CODEN: APDEBX

L9 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Use of neomycin for treating angiogenesis-related diseases
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

L9 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Antioxidant enhancement of therapy for hyperproliferative conditions
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

L9 ANSWER 8 OF 21 MEDLINE
DUPLICATE 1
TI Induction of apoptosis in human mitogen-activated peripheral blood
T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas
receptor/ligand system.
SO BRITISH JOURNAL OF PHARMACOLOGY, (1999 Jun) 127 (4) 813-25.
Journal code: 7502536. ISSN: 0007-1188.

L9 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Clinical pharmacology of anticancer agents in relation to formulations and
administration routes
SO Cancer Treatment Reviews, (1999) 25/2 (83-101).
Refs: 221
ISSN: 0305-7372 CODEN: CTREDJ

L9 ANSWER 10 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Inhibitors of signal transduction: The alkylphosphocholines.
SO Drug News and Perspectives, (1999) 12/2 (69-72).
Refs: 38
ISSN: 0214-0934 CODEN: DNPEED

L9 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Cutaneous lymphomas.
SO Current Problems in Dermatology, (1997) 9/5 (137-204).
Refs: 478
ISSN: 1040-0486 CODEN: APDEBX

L9 ANSWER 12 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [A rational approach to the therapy of cutaneous T-cell lymphomas].
EIN RATIONALER ANSATZ ZUR THERAPIE KUTANER T-ZELL-LYMPHOME.
SO Onkologie, (1996) 19/3 (226-230).
ISSN: 0378-584X CODEN: ONKOD2

L9 ANSWER 13 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Therapeutic approaches in cutaneous lymphoma.
SO Dermatologic Clinics, (1994) 12/2 (433-441).
ISSN: 0733-8635 CODEN: DRMCDJ

L9 ANSWER 14 OF 21 MEDLINE
DUPLICATE 2
TI The amido black assay: a simple and quantitative multipurpose test of
adhesion, proliferation, and cytotoxicity in microplate cultures of
keratinocytes (HaCaT) and other cell types growing adherently or in
suspension.
SO JOURNAL OF IMMUNOLOGICAL METHODS, (1994 Jan 3) 167 (1-2) 1-13.
Journal code: 1305440. ISSN: 0022-1759.

L9 ANSWER 15 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Characteristics of the inhibition of human promyelocytic leukaemia HL60
cell growth by S-D-lactoylglutathione in vitro.
SO Leukemia Research, (1993) Vol. 17, No. 4, pp. 305-310.
ISSN: 0145-2126.

L9 ANSWER 16 OF 21 MEDLINE
DUPLICATE 3
TI In vivo characterization of immunogenicity of a mitoxantrone-resistant
murine P388 leukemia.
SO IN VIVO, (1993 Jan-Feb) 7 (1) 73-9.
Journal code: 8806809. ISSN: 0258-851X.

L9 ANSWER 17 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [New treatment modalities for neoplastic skin diseases].
NEUE BEHANDLUNGSMETHODEN BEI HAUTTUMOREN.
SO Schweizerische Rundschau fur Medizin/Praxis, (1992) 81/19 (610-614).
ISSN: 0369-8394 CODEN: SRMPDJ

L9 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Immunomodulatory activity of hexadecylphosphocholine:
hexadecylphosphocholine-mediated enhancement of T-cell response
SO Cytokines Hemopoiesis, Oncol., AIDS II (1992), 389-95. Editor(s): Freund, Mathias. Publisher: Springer, Berlin, Germany.
CODEN: 59IJAP

L9 ANSWER 19 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI HEXADECYLPHOSPHOCHOLINE INDUCES CYTOKINE EXPRESSION IN HUMAN MONONUCLEAR CELLS.
SO 83RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIFORNIA, USA, MAY 20-23, 1992. PROC AM ASSOC CANCER RES ANNU MEET. (1992) 33 (0), 300.
CODEN: PAMREA.

L9 ANSWER 20 OF 21 MEDLINE
DUPLICATE 4
TI Hexadecylphosphocholine induces interferon-gamma secretion and
expression of GM-CSF mRNA in human mononuclear cells.
SO CELLULAR IMMUNOLOGY, (1992 Apr 15) 141 (1) 161-8.
Journal code: 1246405. ISSN: 0008-8749.

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
TI Hexadecylphosphocholine-mediated enhancement of T-cell responses
to interleukin 2.
SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1) 232-8.
Journal code: 1246405. ISSN: 0008-8749.

=> d 21

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
AN 91356566 MEDLINE
DN 91356566 PubMed ID: 1909215
TI Hexadecylphosphocholine-mediated enhancement of T-cell responses
to interleukin 2.
AU Vehmeyer K; Scheurich P; Eibl H; Unger C
CS Department of Internal Medicine, University of Gottingen, Federal Republic
of Germany.
SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1) 232-8.
Journal code: 1246405. ISSN: 0008-8749.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199110
ED Entered STN: 19911027
Last Updated on STN: 19911027
Entered Medline: 19911004

=> d 21 ab

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
AB The effect of low-dose hexadecylphosphocholine (He-PC) on normal
peripheral mononuclear cells (PMNC) was studied. Interferon-gamma (IFN-g)
production, interleukin 2 (IL-2)
receptor, and HLA-DR antigen expression were investigated, representing
typical T-cell activation parameters. In PMNC cultures, He-PC
dose-dependently enhanced the production of IFN-g, provided IL-
2 had been added exogenously. Without IL-2
He-PC was ineffective. In some cultures, at a concentration of 8
micrograms/ml He-PC stimulated the secretion of IFN-g more than 20-fold
compared to untreated controls. Although He-PC by itself lacked mitogenic
activity, this compound also stimulated IFN-g production in the presence
of suboptimal doses of phytohemagglutinin (PHA). Immunofluorescence
studies demonstrated that He-PC also increased IL-2
receptor and HLA-DR antigen expression under these experimental
conditions. Taken together, these results indicate that He-PC may possess
immunomodulatory activity also in vivo, acting as a costimulator for the
IL-2-mediated T-cell activation process.

=> d 21 au ti so

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
AU Vehmeyer K; Scheurich P; Eibl H; Unger C
TI Hexadecylphosphocholine-mediated enhancement of T-cell responses
to interleukin 2.
SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1) 232-8.
Journal code: 1246405. ISSN: 0008-8749.

=>
Connection closed by remote host

=> fil medline biosis cancerlit caplus embase
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 16:48:12 ON 16 JUL 2003

FILE 'BIOSIS' ENTERED AT 16:48:12 ON 16 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CANCERLIT' ENTERED AT 16:48:12 ON 16 JUL 2003

FILE 'CAPLUS' ENTERED AT 16:48:12 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:48:12 ON 16 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s hexadecylphosphocholine or miltefosine
L1 1680 HEXADECYLPHOSPHOCHOLINE OR MILTEFOSINE

=> s l1 and (il-2 or interleukin-2)
L2 39 L1 AND (IL-2 OR INTERLEUKIN-2)

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 21 DUP REM L2 (18 DUPLICATES REMOVED)

=> d 1-11 ti so

L3 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Incensole and furanogermacrens and compounds in treatment for inhibiting
neoplastic lesions and microorganisms
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

L3 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Methods and compositions for enhancing pharmaceutical treatments
SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.
CODEN: USXXCO

L3 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Therapeutic modulation of the tumor inflammatory response
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO

L3 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Combination product intended for carrying out a cytotoxic treatment, in
particular an antitumour treatment, in a mammal
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L3 ANSWER 5 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Cutaneous lymphomas.
SO Current Problems in Dermatology, (2000) 12/1 (25-29).
Refs: 25
ISSN: 1040-0486 CODEN: APDEBX

L3 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Use of neomycin for treating angiogenesis-related diseases
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

L3 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Antioxidant enhancement of therapy for hyperproliferative conditions
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

L3 ANSWER 8 OF 21 MEDLINE
DUPLICATE 1
TI Induction of apoptosis in human mitogen-activated peripheral blood
T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas
receptor/ligand system.
SO BRITISH JOURNAL OF PHARMACOLOGY, (1999 Jun) 127 (4) 813-25.
Journal code: 7502536. ISSN: 0007-1188.

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Clinical pharmacology of anticancer agents in relation to formulations and
administration routes.
SO Cancer Treatment Reviews, (1999) 25/2 (83-101).
Refs: 221
ISSN: 0305-7372 CODEN: CTREDJ

L3 ANSWER 10 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Inhibitors of signal transduction: The alkylphosphocholines.
SO Drug News and Perspectives, (1999) 12/2 (69-72).
Refs: 38
ISSN: 0214-0934 CODEN: DNPEED

L3 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Cutaneous lymphomas.
SO Current Problems in Dermatology, (1997) 9/5 (137-204).
Refs: 478
ISSN: 1040-0486 CODEN: APDEBX

=> d 9 ab

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AB In the past years, alternative administration routes and pharmaceutical
formulations of anticancer agents have been investigated in order to
improve conventional chemotherapy treatment. The impact of these
adjustments on the pharmacokinetics and pharmacodynamics is discussed. A
review of the literature shows many examples of alternative administration
forms of anticancer agents with improved pharmacokinetics. Local
administration routes have been investigated in order to reduce the
systemic toxicity and to enhance the local efficacy of conventional
chemotherapy. Oral administration of anticancer agents is preferred by
patients for its convenience and its potential for outpatient treatment.
In addition, oral administration facilitates a prolonged exposure to the
cytotoxic agent. However, poor bioavailability and substantial
interpatient variability are noted as limitations for oral chemotherapy.
Increased tumour selectivity can also be achieved by the use of specific
pharmaceutical formulations, such as liposomes and macromolecular drug
conjugates. The composition of these formulations often determine the
pharmacokinetic behaviour of the formulated drug. In conclusion, several
alternative administration forms of anticancer agents have been designed
in the past years, with the potential for improvement of conventional
chemotherapy, however, more extensive clinical evaluation of these novel
strategies is warranted to prove their real clinical value.

=> d 9 kwic

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
CT Medical Descriptors:
drug . . .
DT, drug therapy
cyclophosphamide: PK, pharmacokinetics
bisacetatoammine dichlorocyclohexylamineplatinum: AD, drug administration
bisacetatoammine dichlorocyclohexylamineplatinum: DT, drug therapy
bisacetatoammine dichlorocyclohexylamineplatinum: PK, pharmacokinetics
trofosfamide: AD, drug administration
trofosfamide: DT, drug therapy
trofosfamide: PK, pharmacokinetics
miltefosine: AD, drug administration
miltefosine: DT, drug therapy
miltefosine: PK, pharmacokinetics
lurtotecan: AD, drug administration
lurtotecan: DT, drug therapy
lurtotecan: PK, pharmacokinetics
doxifluridine: AD, drug administration
doxifluridine: DT, drug therapy
doxifluridine: PK, pharmacokinetics
UFT: AE, adverse. . . 5' myristylphosphate: AE, adverse drug reaction
floxuridine 5' myristylphosphate: CT, clinical trial
floxuridine 5' myristylphosphate: AD, drug administration
floxuridine 5' myristylphosphate: DT, drug therapy
interleukin 2: AD, drug administration
interleukin 2: DT, drug therapy
unindexed drug
RN. . . 23541-50-6; (idarubicin) 57852-57-0, 58957-92-9; (etoposide)
33419-42-0; (teniposide) 29767-20-2; (vincristine) 57-22-7; (vinblastine)
865-21-4, (vindesine) 53643-48-4; (cyclophosphamide) 50-18-0;
(bisacetatoammine dichlorocyclohexylamineplatinum) 129580-63-8;
(trofosfamide) 22089-22-1; (miltefosine) 58066-85-6; (lurtotecan) 149882-10-0, 155773-58-3; (doxifluridine) 3094-09-5; (UFT)
74578-38-4; (capecitabine) 154361-50-9; (carmofur) 61422-45-5;
(floxuridine 5' myristylphosphate) 86976-77-4; (interleukin
2) 85898-30-2

=> d 9 au ti so

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AU Meerum Terwogt J.M.; Schellens J.H.M.; Ten Bokkel Huinink W.W.; Beijnen
J.H.
TI Clinical pharmacology of anticancer agents in relation to formulations and
administration routes.
SO Cancer Treatment Reviews, (1999) 25/2 (83-101).
Refs: 221
ISSN: 0305-7372 CODEN: CTREDJ

=> d 11 ab

L3 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AB The skin is on of the organs most frequently affected by extranodal
lymphomas. Cutaneous lymphomas are peculiar in many aspects. (1) In
contrast to nodal lymphomas, cutaneous T-cell lymphomas are more frequent
than B-cell lymphomas. (2) Cutaneous T-cell lymphomas develop in a
multistep process, exhibiting distinct clinical, histologica, and
molecular-biologic features. They progress very slowly over a period of
years or decades. (3) The disease becomes manifest very early on. (4) The
skin provides a unique structural and humoral (cytokines) microenvironment
to attract T cells and B cells to home to under distinct promotional
conditions. (5) Treatment strategies for cutaneous lymphomas are quite
different from those for nodal lymphomas.

=> d 11 kwic

L3 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
CT Medical Descriptors:
*skin . . .
drug combination
cyclophosphamide: DT, drug therapy
doxorubicin: CB, drug combination
doxorubicin: DT, drug therapy
vincristine: CB, drug combination
vincristine: DT, drug therapy
monoclonal antibody: DT, drug therapy
miltefosine: CT, clinical trial
miltefosine: DT, drug therapy
interleukin 2
methotrexate: DT, drug therapy
cisplatin: DT, drug therapy
etoposide: DT, drug therapy
teniposide: DT, drug therapy
fludarabine: DT, drug therapy
pentostatin: DT, drug therapy
bleomycin: DT,. . .
RN. . . (etretinate) 54350-48-0; (etretin) 55079-83-9; (isotretinoin)
4759-48-2; (gamma interferon) 82115-62-6; (prednisone) 53-03-2;
(chlorambucil) 305-03-3; (cyclophosphamide) 50-18-0; (doxorubicin)
23214-92-8, 25316-40-9; (vincristine) 57-22-7; (miltefosine)
58066-85-6; (interleukin 2) 85898-30-2; (methotrexate)
15475-56-6, 59-05-2, 7413-34-5; (cisplatin) 15663-27-1, 26035-31-4,
96081-74-2; (etoposide) 33419-42-0; (teniposide) 29767-20-2; (fludarabine)
21679-14-1; (pentostatin) 53910-25-1; (bleomycin) 11056-06-7; (vindesine).
. .

=> d 12-21 ti so

L3 ANSWER 12 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [A rational approach to the therapy of cutaneous T-cell lymphomas].
EIN RATIONALER ANSATZ ZUR THERAPIE KUTANER T-ZELL-LYMPHOME.
SO Onkologie, (1996) 19/3 (226-230).
ISSN: 0378-584X CODEN: ONKOD2

L3 ANSWER 13 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Therapeutic approaches in cutaneous lymphoma.
SO Dermatologic Clinics, (1994) 12/2 (433-441).
ISSN: 0733-8635 CODEN: DRMCDJ

L3 ANSWER 14 OF 21 MEDLINE
DUPLICATE 2

TI The amido black assay: a simple and quantitative multipurpose test of
adhesion, proliferation, and cytotoxicity in microplate cultures of
keratinocytes (HaCaT) and other cell types growing adherently or in
suspension.
SO JOURNAL OF IMMUNOLOGICAL METHODS, (1994 Jan 3) 167 (1-2) 1-13.
Journal code: 1305440. ISSN: 0022-1759.

L3 ANSWER 15 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Characteristics of the inhibition of human promyelocytic leukaemia HL60
cell growth by S-D-lactoylglutathione in vitro.
SO Leukemia Research, (1993) Vol. 17, No. 4, pp. 305-310.
ISSN: 0145-2126.

L3 ANSWER 16 OF 21 MEDLINE DUPLICATE 3
TI In vivo characterization of immunogenicity of a mitoxantrone-resistant
murine P388 leukemia.
SO IN VIVO, (1993 Jan-Feb) 7 (1) 73-9.
Journal code: 8806809. ISSN: 0258-851X.

L3 ANSWER 17 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [New treatment modalities for neoplastic skin diseases].
NEUE BEHANDLUNGSMETHODEN BEI HAUTTUMOREN.
SO Schweizerische Rundschau fur Medizin/Praxis, (1992) 81/19 (610-614).
ISSN: 0369-8394 CODEN: SRMPDJ

L3 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS
TI Immunomodulatory activity of hexadecylphosphocholine:
hexadecylphosphocholine-mediated enhancement of T-cell response
SO Cytokines Hemopoiesis, Oncol., AIDS II (1992), 389-95. Editor(s): Freund,
Mathias. Publisher: Springer, Berlin, Germany.
CODEN: 59IJAP

L3 ANSWER 19 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI HEXADECYLPHOSPHOCHOLINE INDUCES CYTOKINE EXPRESSION IN HUMAN
MONONUCLEAR CELLS.
SO 83RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN
DIEGO, CALIFORNIA, USA, MAY 20-23, 1992. PROC AM ASSOC CANCER RES ANNU
MEET. (1992) 33 (0), 300.
CODEN: PAMREA.

L3 ANSWER 20 OF 21 MEDLINE DUPLICATE 4
TI Hexadecylphosphocholine induces interferon-gamma secretion and
expression of GM-CSF mRNA in human mononuclear cells.
SO CELLULAR IMMUNOLOGY, (1992 Apr 15) 141 (1) 161-8.
Journal code: 1246405. ISSN: 0008-8749.

L3 ANSWER 21 OF 21 MEDLINE DUPLICATE 5
TI Hexadecylphosphocholine-mediated enhancement of T-cell responses
to interleukin 2.
SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1) 232-8.
Journal code: 1246405. ISSN: 0008-8749.

=> d 16 ab

L3 ANSWER 16 OF 21 MEDLINE DUPLICATE 3
AB The Mitoxantrone-resistant murine leukemia P388/Mitox, expressing the
multidrug-resistant phenotype, has a higher immunogenicity than the parent
sensitive P388. This could be shown in vivo by immunization with
lethally-irradiated tumor cells. If the P388/Mitox was used for
immunization before subsequent challenge with viable tumor cells of the
same line, this resulted in a partial rejection of tumors and production
of a substantial number of tumor-free survivors. For an effective
immunization at least two primings s.c., i.v. or i.p. with at least 10(6)
irradiated cells were necessary. This protected the recipient mice from a
challenge of up to 10(8) viable cells over a period of at least 75 days.
Treatment of BDF1 mice with the T-cell suppressor Cyclosporin A prevents
immunization. In nude mice no immunization effect could be obtained. It
was possible to transfer immunity adoptively with spleen cells from mice,
which were treated with irradiated tumor cells of the P388/Mitox line.
Treatment of tumor-bearing mice with IL-2 resulted in a prolongation of survival both when it was administered prophylactically
before transplantation of P388/Mitox and at an advanced stage (day 7-11).
Also the alkyl-phosphocholine hexadecylphosphocholine was
significantly effective in the resistant but not in the parent P388
leukemia. The data presented demonstrate that by development of a
multidrug-resistance, concomitantly a xenogenization must have taken place
which leads to a recognition of cells by immune mechanisms. In our model,
T-lymphocytes and NK-/LAK-cells probably play a role in the
immunologically conditioned rejection of tumor cells of the P388/Mitox
leukemia.(ABSTRACT TRUNCATED AT 250 WORDS)

=> d 18 ab

L3 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS
AB The effect of low-dose hexadecylphosphocholine (He-PC) on normal
peripheral mononuclear cells (PMNC) was studied. Interferon-.gamma.
(IFN-.gamma.) prodn., interleukin-2 (IL-
2) receptor and HLA-DR antigen expression were investigated,
representing typical T-cell activation parameters. In PMNC cultures,
He-PC dose-dependently enhanced the prodn. of IFN-.gamma., provided
IL-2 had been added exogenously. Without IL-
2 He-PC was ineffective. In some cultures, at a concn. of 8
.mu g/mL He-PC stimulated the secretion of IFN-.gamma. 20-fold as compared
to untreated controls. Although He-PC by itself lacked mitogenic
activity, this compd. stimulated IFN-.gamma. prodn. in the presence of
suboptimal doses of phytohemagglutinin. Immunofluorescence studies
demonstrated that He-PC also increased IL-2 receptor
and HLA-DR antigen expression under these exptl. conditions. Thus, He-PC
may possess immunomodulatory activity also in vivo, acting as a
costimulator for the IL-2-mediated T-cell activation
process.

=> d 21 ab

L3 ANSWER 21 OF 21 MEDLINE DUPLICATE 5
AB The effect of low-dose hexadecylphosphocholine (He-PC) on normal
peripheral mononuclear cells (PMNC) was studied. Interferon-gamma (IFN-g)
production, interleukin 2 (IL-2)
receptor, and HLA-DR antigen expression were investigated, representing
typical T-cell activation parameters. In PMNC cultures, He-PC
dose-dependently enhanced the production of IFN-g, provided IL-
2 had been added exogenously. Without IL-2
He-PC was ineffective. In some cultures, at a concentration of 8
micrograms/ml He-PC stimulated the secretion of IFN-g more than 20-fold
compared to untreated controls. Although He-PC by itself lacked mitogenic
activity, this compound also stimulated IFN-g production in the presence
of suboptimal doses of phytohemagglutinin (PHA). Immunofluorescence
studies demonstrated that He-PC also increased IL-2
receptor and HLA-DR antigen expression under these experimental
conditions. Taken together, these results indicate that He-PC may possess
immunomodulatory activity also in vivo, acting as a costimulator for the
IL-2-mediated T-cell activation process.

=> log odd
'ODD' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 16:57:26 ON 16 JUL 2003

=> fil medline caplus cancerlit
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 20:39:20 ON 23 JUL 2003

FILE 'CAPLUS' ENTERED AT 20:39:20 ON 23 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 20:39:20 ON 23 JUL 2003

=> s Rolland-A?/au
L1 323 ROLLAND-A?/AU

=> s l1 and catinonic
L2 0 L1 AND CATINONIC

=> s retrovirus (s) il-2
L3 387 RETROVIRUS (S) IL-2

=> s l3 and (treat? or therap?)
L4 177 L3 AND (TREAT? OR THERAP?)

=> s chon?/au
L5 9207 CHON?/AU

=> s l5 and lipid
L6 220 L5 AND LIPID

=> s l6 and vector
L7 5 L6 AND VECTOR

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 4 DUP REM L7 (1 DUPLICATE REMOVED)

=> d 1-4 au ti so

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
IN Tam, Patrick; Chonn, Arcadio
TI Liposomal delivery of adeno-associated virus vectors
SO U.S., 14 pp.
CODEN: USXXAM

L8 ANSWER 2 OF 4 MEDLINE on STN DUPLICATE 1
AU Schoen P; Chonn A; Cullis P R; Wilschut J; Scherrer P
TI Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles.
SO GENE THERAPY, (1999 May) 6 (5) 823-32.
Journal code: 9421525. ISSN: 0969-7128.

L8 ANSWER 3 OF 4 MEDLINE on STN
AU Lim S K; Kim H; Lim S K; bin Ali A; Lim Y K; Wang Y; Chong S M; Costantini F; Baumman H
TI Increased susceptibility in Hp knockout mice during acute hemolysis.
SO BLOOD, (1998 Sep 15) 92 (6) 1870-7.
Journal code: 7603509. ISSN: 0006-4971.

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
IN Chong, Pele; Kandil, Ali; Sia, Charles; Klein, Michel H.
TI Synthetic Haemophilus influenzae vaccines comprising outer membrane protein antigenic determinants conjugated to oligoribosylribitol phosphate
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2

=> s Chonn?/au
L9 45 CHONN?/AU

=> s l9 and lipid
L10 24 L9 AND LIPID

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11 16 DUP REM L10 (8 DUPLICATES REMOVED)

=> d 1-16 ti so

L11 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
TI Liposomal delivery of adeno-associated virus vectors
SO U.S., 14 pp.
CODEN: USXXAM

L11 ANSWER 2 OF 16 MEDLINE on STN DUPLICATE 1
TI Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles.
SO GENE THERAPY, (1999 May) 6 (5) 823-32.
Journal code: 9421525. ISSN: 0969-7128.

L11 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
TI Stabilization and regulated fusion of liposomes containing a cationic lipid using amphipathic polyethylene glycol derivatives
SO Journal of Liposome Research (1998), 8(2), 195-211
CODEN: JLREE7; ISSN: 0898-2104

L11 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
TI Recent advances in liposome technologies and their applications for systemic gene delivery
SO Advanced Drug Delivery Reviews (1998), 30(1-3), 73-83
CODEN: ADDREP; ISSN: 0169-409X

L11 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
TI Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behavior in vivo
SO Advanced Drug Delivery Reviews (1998), 32(1,2), 3-17
CODEN: ADDREP; ISSN: 0169-409X

L11 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
TI Liposome-blood protein interactions in relation to liposome clearance.
SO Book of Abstracts, 213th ACS National Meeting, San Francisco, April 13-17 (1997), PMSE-300 Publisher: American Chemical Society, Washington, D. C.
CODEN: 64AOAA

L11 ANSWER 7 OF 16 MEDLINE on STN DUPLICATE 2
TI Influence of cholesterol on the association of plasma proteins with liposomes.
SO BIOCHEMISTRY, (1996 Feb 27) 35 (8) 2521-5.
Journal code: 0370623. ISSN: 0006-2960.

L11 ANSWER 8 OF 16 MEDLINE on STN DUPLICATE 3
TI Influence of dose on liposome clearance: critical role of blood proteins.
SO BIOCHIMICA ET BIOPHYSICA ACTA, (1996 May 22) 1281 (1) 31-7.
Journal code: 0217513. ISSN: 0006-3002.

L11 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
TI Virosome-mediated intracellular delivery of therapeutic agents
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2

L11 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
TI Method using reduction of plasma apolipoprotein H for inhibiting the clearance of liposomes from the circulation
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2

L11 ANSWER 11 OF 16 MEDLINE on STN DUPLICATE 4
TI Liposome-complement interactions in rat serum: implications for liposome survival studies.
SO BIOCHIMICA ET BIOPHYSICA ACTA, (1994 Apr 20) 1191 (1) 43-51.
Journal code: 0217513. ISSN: 0006-3002.

L11 ANSWER 12 OF 16 MEDLINE on STN DUPLICATE 5
TI Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
SO JOURNAL OF IMMUNOLOGY, (1993 Aug 15) 151 (4) 2159-65.
Journal code: 2985117R. ISSN: 0022-1767.

L11 ANSWER 13 OF 16 MEDLINE on STN DUPLICATE 6
TI Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1992 Sep 15) 267 (26) 18759-65.
Journal code: 2985121R. ISSN: 0021-9258.

L11 ANSWER 14 OF 16 MEDLINE on STN DUPLICATE 7
TI The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes.
SO JOURNAL OF IMMUNOLOGY, (1991 Jun 15) 146 (12) 4234-41.
Journal code: 2985117R. ISSN: 0022-1767.

L11 ANSWER 15 OF 16 MEDLINE on STN DUPLICATE 8
TI Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size.
SO BIOCHIMICA ET BIOPHYSICA ACTA, (1991 Jan 9) 1061 (1) 56-64.
Journal code: 0217513. ISSN: 0006-3002.

L11 ANSWER 16 OF 16 MEDLINE on STN
TI The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).
SO BLOOD, (1985 Dec) 66 (6) 1476-8.
Journal code: 7603509. ISSN: 0006-4971.

=> s CHonn?/au and 1995/py
L12 5 CHONN?/AU AND 1995/PY

=> d 1-5 au ti so

L12 ANSWER 1 OF 5 MEDLINE on STN
AU Chonn A; Cullis P R
TI Recent advances in liposomal drug-delivery systems.

SO CURRENT OPINION IN BIOTECHNOLOGY, (1995 Dec) 6 (6) 698-708.
Ref: 120
Journal code: 9100492. ISSN: 0958-1669.

L12 ANSWER 2 OF 5 MEDLINE on STN
AU Chonn A; Semple S C; Cullis P R
TI Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1995 Oct 27) 270 (43) 25845-9.
Journal code: 2985121R. ISSN: 0021-9258.

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
IN Wilschut, Jan C.; Scherrer, Peter; Chonn, Arcadio
TI Virosome-mediated intracellular delivery of therapeutic agents
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AU Chonn, Arcadio; Cullis, Pieter R.
TI Recent advances in liposomal drug-delivery systems
SO Current Opinion in Biotechnology (1995), 6(6), 698-708
CODEN: CUOBE3; ISSN: 0958-1669

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AU Chonn, Arcadio; Semple, Sean C.; Cullis, Pieter R.
TI .beta.2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles
SO Journal of Biological Chemistry (1995), 270(43), 25845-9
CODEN: JBCHA3; ISSN: 0021-9258

=> d l ab

L12 ANSWER 1 OF 5 MEDLINE on STN
AB Liposomal drug-delivery systems have come of age in recent years, with several liposomal drugs currently in advanced clinical trials or already on the market. It is clear from numerous pre-clinical and clinical studies that drugs, such as antitumor drugs, packaged in liposomes exhibit reduced toxicities, while retaining, or gaining enhanced, efficacy. This results, in part, from altered pharmacokinetics, which lead to drug accumulation at disease sites, such as tumors, and reduced distribution to sensitive tissues. Fusogenic liposomal systems that are under development have the potential to deliver drugs intracellularly, and this is expected to markedly enhance therapeutic activity. Advances in liposome design are leading to new applications for the delivery of new biotechnology products, such as recombinant proteins, antisense oligonucleotides and cloned genes.

=> s Chonn-A?/au and liposom?
L13 37 CHONN-A?/AU AND LIPOSOM?

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14 24 DUP REM L13 (13 DUPLICATES REMOVED)

=> s l14 and review/dt
L15 5 L14 AND REVIEW/DT

=> d 1-5 au ti so

L15 ANSWER 1 OF 5 MEDLINE on STN
AU Chonn A; Cullis P R
TI Recent advances in liposomal drug-delivery systems.
SO CURRENT OPINION IN BIOTECHNOLOGY, (1995 Dec) 6 (6) 698-708.
Ref: 120
Journal code: 9100492. ISSN: 0958-1669.

L15 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AU Semple, Sean C.; Chonn, Arcadio; Cullis, Pieter R.
TI Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behavior in vivo
SO Advanced Drug Delivery Reviews (1998), 32(1,2), 3-17
CODEN: ADDREP; ISSN: 0169-409X

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AU Chonn, Arcadio; Cullis, Pieter R.
TI Recent advances in liposome technologies and their applications for systemic gene delivery
SO Advanced Drug Delivery Reviews (1998), 30(1-3), 73-83
CODEN: ADDREP; ISSN: 0169-409X

L15 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AU Semple, Sean C.; Chonn, Arcadio
TI Liposome-blood protein interactions in relation to liposome clearance
SO Journal of Liposome Research (1996), 6(1), 33-60
CODEN: JLREE7; ISSN: 0898-2104

L15 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AU Chonn, Arcadio; Cullis, Pieter R.
TI Ganglioside GM1 and hydrophilic polymers increase liposome circulation times by inhibiting the association of blood proteins
SO Journal of Liposome Research (1992), 2(3), 397-410
CODEN: JLREE7; ISSN: 0898-2104

=> d 3 ab

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AB A review with 104 refs. The recent clin. successes experienced by liposomal drug delivery systems stem from the ability to produce well-defined liposomes that can be composed of a wide variety of lipids, have high drug-trapping efficiencies and have a narrow size distribution, averaging less than 100 nm in diam. Agents that prolong the circulation lifetime of liposomes, enhance the delivery of liposomal drugs to specific target cells, or enhance the ability of liposomes to deliver drugs intracellularly can be incorporated to further increase the therapeutic activity. The phys. and chem. requirements for optimum liposome drug delivery systems will likely apply to lipid-based gene delivery systems. As a result, the development of liposomal delivery systems for systemic gene delivery should follow similar strategies.

=> d 3 au ti so ab

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AU Chonn, Arcadio; Cullis, Pieter R.
TI Recent advances in liposome technologies and their applications for systemic gene delivery
SO Advanced Drug Delivery Reviews (1998), 30(1-3), 73-83
CODEN: ADDREP; ISSN: 0169-409X
AB A review with 104 refs. The recent clin. successes experienced by liposomal drug delivery systems stem from the ability to produce well-defined liposomes that can be composed of a wide variety of lipids, have high drug-trapping efficiencies and have a narrow size distribution, averaging less than 100 nm in diam. Agents that prolong the circulation lifetime of liposomes, enhance the delivery of liposomal drugs to specific target cells, or enhance the ability of liposomes to deliver drugs intracellularly can be incorporated to further increase the therapeutic activity. The phys. and chem. requirements for optimum liposome drug delivery systems will likely apply to lipid-based gene delivery systems. As a result, the development of liposomal delivery systems for systemic gene delivery should follow similar strategies.

=> s DOPE (S) adjuvant
L16 8 DOPE (S) ADJUVANT

=> dup rem l16
PROCESSING COMPLETED FOR L16
L17 8 DUP REM L16 (0 DUPLICATES REMOVED)

=> d 1-8 au ti so

L17 ANSWER 1 OF 8 CANCERLIT on STN
AU D'Souza S; Rosseels V; Denis O; Tanghe A; De Smet N; Jurion F; Palfliet K;
Castiglioni N; Vanonckelen A; Wheeler C; Huygen K
TI Improved tuberculosis DNA vaccines by formulation in cationic lipids.
SO INFECTION AND IMMUNITY, (2002 Jul) 70 (7) 3681-8.
Journal code: 0246127. ISSN: 0019-9567.

L17 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
IN Meyer, Olivier
TI Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L17 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
IN Ellis, John Albert; Allan, Gordon Moore; Meehan, Brian; Clark, Edward; Haines, Deborah; Hassard, Lori; Harding, John; Charreyre, Catherine Elisabeth; Chappuis, Gilles Emile; Krakowka, George Steve; Audonnet, Jean-Christophe Francis; McNeilly, Francis
TI Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2

L17 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hermanson, Gary George
TI cDNAs encoding the Flt-3 receptor ligand and there use as adjuvants in vector vaccines
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

L17 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
IN Audonnet, Jean-Christophe Francis; Baudu, Philippe Guy Nicolas; Brunet, Sylvie Claudine
TI Feline calicivirus genes and vaccines, in particular recombined vaccines

SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2

L17 ANSWER 6 OF 8 CANCERLIT on STN
AU Guy B; Pascal N; Francon A; Bonnin A; Gimenez S; Lafay-Vialon E; Trannoy
E; Haensler J
TI Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
SO VACCINE, (2001 Feb 8) 19 (13-14) 1794-805.
Journal code: 8406899. ISSN: 0264-410X.

L17 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
IN Wheeler, Carl J.
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L17 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AU Norman, Jon; Hartikka, Jukka; Strauch, Pamela; Manthorpe, Marston
TI Adjuvants for plasmid DNA vaccines
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

=> s DOPE and adjuvant and review/dt
L18 1 DOPE AND ADJUVANT AND REVIEW/DT

=> d

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:679109 CAPLUS
DN 132:164839
TI Adjuvants for plasmid DNA vaccines
AU Norman, Jon; Hartikka, Jukka; Strauch, Pamela; Manthorpe, Marston
CS Vical Inc., San Diego, CA, USA
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN
PB Humana Press Inc.
DT Journal; General Review
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l ab

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AB A review with 38 refs. discussing the effects of the co-injection of bupivacaine (BP), polyvinyl pyrollidone (PVP), or DMRIE:DOPE cationic liposomes on plasmid DNA-mediated luciferase gene expression and antibody responses to influenza nucleoprotein (NP) antigen.

=> s DOPE and adjuvant
L19 28 DOPE AND ADJUVANT

=> dup rem l19
PROCESSING COMPLETED FOR L19
L20 24 DUP REM L19 (4 DUPLICATES REMOVED)

=> d 15-24 ti so

L20 ANSWER 15 OF 24 MEDLINE on STN DUPLICATE 2
TI Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
SO VACCINE, (2001 Feb 8) 19 (13-14) 1794-805.
Journal code: 8406899. ISSN: 0264-410X.

L20 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI In vivo immune responses induced by CpG oligonucleotides encapsulated in sterically stabilized cationic liposomes
SO Proceedings - 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001 (2001), Volume 2, 1057-1058
Publisher: Controlled Release Society, Minneapolis, Minn.
CODEN: 69CNY8

L20 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Porcine circovirus vaccine
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L20 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L20 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Method for transferring an gene of interest into a cell by using C1 complement factor subunit and uses thereof in gene therapy
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW

L20 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvants for plasmid DNA vaccines
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L20 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Transfecting compositions comprising DNA-binding, disulfide bond-containing compounds and their use in gene therapy
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

L20 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes
SO Vaccine (1999), 17(11-12), 1540-1548
CODEN: VACCDE; ISSN: 0264-410X

L20 ANSWER 23 OF 24 MEDLINE on STN
TI Transfection of cultured myoblasts in high serum concentration with DODAC:
DOPE liposomes.
SO GENE THERAPY, (1998 Oct) 5 (10) 1306-13.
Journal code: 9421525. ISSN: 0969-7128.

L20 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protamine sulfate enhances lipid-mediated gene transfer
SO Gene Therapy (1997), 4(9), 961-968
CODEN: GETHEC; ISSN: 0969-7128

=> d 23 ab

L20 ANSWER 23 OF 24 MEDLINE on STN
AB The inhibitory effect of serum is one of the main obstacles to the in vivo use of cationic liposomes as a DNA delivery system. We have found that a novel liposome formulation, DODAC:DOPE (1:1) is totally resistant to the inhibitory effects of serum for transfection of cultured myoblasts and myotubes. Transfection with a lacZ reporter gene in the presence of 95% fetal bovine serum gave up to 25% beta-gal-positive cells in C2C12 myoblasts and about six-fold less in primary human myoblasts. The lower transgene expression in primary cells does not appear to be a result of less DNA uptake but might result from differences in intracellular trafficking of the complexes. DODAC-based liposomes are unique in their resistance to serum inhibition and may therefore be valuable for the systemic delivery of genetic information to muscle and other tissues.

=> s (dioleoylphosphatidylethanolamine or DOPE) and adjuvant
L21 33 (DIOLEOYLPHOSPHATIDYLETHANOLAMINE OR DOPE) AND ADJUVANT

=> dup rem l21
PROCESSING COMPLETED FOR L21
L22 29 DUP REM L21 (4 DUPLICATES REMOVED)

=> d 15-29 ti so

L22 ANSWER 15 OF 29 MEDLINE on STN DUPLICATE 2
TI Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
SO VACCINE, (2001 Feb 8) 19 (13-14) 1794-805.
Journal code: 8406899. ISSN: 0264-410X.

L22 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI In vivo immune responses induced by CpG oligonucleotides encapsulated in sterically stabilized cationic liposomes
SO Proceedings - 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001 (2001), Volume 2, 1057-1058
Publisher: Controlled Release Society, Minneapolis, Minn.
CODEN: 69CNY8

L22 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Surface-Linked Liposomal Antigen Induces IgE-Selective Unresponsiveness Regardless of the Lipid Components of Liposomes
SO Bioconjugate Chemistry (2001), 12(3), 391-395
CODEN: BCCHES; ISSN: 1043-1802

L22 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Porcine circovirus vaccine
SO PCT Int. Appl., 40 pp
CODEN: PIXXD2

L22 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L22 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Method for transferring an gene of interest into a cell by using C1 complement factor subunit and uses thereof in gene therapy
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW

L22 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Activation of host antitumoral responses by cationic lipid/DNA complexes
SO Cancer Gene Therapy (2000), 7(3), 353-359
CODEN: CGTHEG; ISSN: 0929-1903

L22 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvants for plasmid DNA vaccines
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L22 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Transfecting compositions comprising DNA-binding, disulfide bond-containing compounds and their use in gene therapy
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

L22 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes
SO Vaccine (1999), 17(11-12), 1540-1548
CODEN: VACCDE; ISSN: 0264-410X

L22 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Methods for in vivo gene transfer into bladder without viral vectors
SO Osaka-shi Igakkai Zasshi (1999), 48(3-4), 435-442
CODEN: OIGZDE; ISSN: 0386-4103

L22 ANSWER 26 OF 29 MEDLINE on STN
TI Transfection of cultured myoblasts in high serum concentration with DODAC:
DOPE liposomes.
SO GENE THERAPY, (1998 Oct) 5 (10) 1306-13.
Journal code: 9421525. ISSN: 0969-7128.

L22 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Novel adjuvant compositions and vaccine formulations comprising same
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2

L22 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protamine sulfate enhances lipid-mediated gene transfer
SO Gene Therapy (1997), 4(9), 961-968
CODEN: GETHEC; ISSN: 0969-7128

L22 ANSWER 29 OF 29 CANCERLIT on STN
TI PH-SENSITIVE LIPOSOMES FOR THE DELIVERY OF IMMUNOMODULATORS.
SO UCLA Symp Mol Cell Biol, (1989) New Ser 89 427-39.

=> d 27 ab

L22 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
AB An adjuvant for administration to a host animal to enhance immune response, comprising a polysaccharide-phospholipid conjugate, whose polysaccharide moiety may for example comprise a modified glucan, chitosan, or alginate polysaccharide, conjugated to a phospholipid. The adjuvant may be suitably formulated with an antigen to provide a therapeutic vaccine for a variety of disease states and/or physiol. conditions.

=> d 27

L22 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:181130 CAPLUS
DN 126:176905
TI Novel adjuvant compositions and vaccine formulations comprising same
IN Parikh, Indu
PA Research Triangle Pharmaceuticals, USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9701330	A1	19970116	WO 1996-US11051	19960626
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2219904	AA	19970116	CA 1996-2219904	19960626
AU 9664007	A1	19970130	AU 1996-64007	19960626
EP 857059	A1	19980812	EP 1996-923519	19960626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001523216	T2	20011120	JP 1997-504586	19960626
PRAI US 1995-464969	A	19950626		
WO 1996-US11051	W	19960626		

=>